{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T19:10:04Z","timestamp":1793214604426,"version":"4.5.0"},"reference-count":30,"publisher":"The Journal of Rheumatology","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Rheumatol"],"published-print":{"date-parts":[[2012,2]]},"abstract":"<jats:sec><jats:title>Objective.<\/jats:title><jats:p>To describe 3 cases of scleritis associated with etanercept use for rheumatoid arthritis (RA) and to review the literature related to inflammatory eye diseases associated with the use of etanercept.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods.<\/jats:title><jats:p>Three cases of severe scleritis during etanercept therapy were analyzed. A systematic review of the literature in PubMed, Embase, and the Cochrane Library was performed, from 1962 to July 2010.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results.<\/jats:title><jats:p>Three patients with seropositive RA developed scleritis 7\u201328 months after initiation of etanercept, for the first time during their long-lasting disease. In all patients the underlying disease had responded well to anti-tumor necrosis factor therapy. Ocular inflammation went into remission after discontinuation of etanercept, and no other relapses were observed. One patient experienced a dechallenge-rechallenge phenomenon (improvement in symptoms following discontinuation of the agent, then reappearance or worsening of symptoms on reexposure to the agent). Forty-two cases of inflammatory eye diseases believed to be associated with the use of etanercept have been reported in the literature: 33 uveitis, 8 scleritis, 1 orbital myositis, concerning 16 patients with RA, 10 with juvenile idiopathic arthritis, 14 with ankylosing spondylitis, and 2 with psoriatic spondyloarthropathy. Dechallenge was performed in 28 patients, leading to resolution of symptoms. Rechallenge was done in 6 cases, with clear exacerbation.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion.<\/jats:title><jats:p>Ocular inflammation is paradoxically a potential adverse effect of etanercept, even in previously uninvolved eyes.<\/jats:p><\/jats:sec>","DOI":"10.3899\/jrheum.110865","type":"journal-article","created":{"date-parts":[[2011,12,16]],"date-time":"2011-12-16T01:25:32Z","timestamp":1323998732000},"page":"233-239","source":"Crossref","is-referenced-by-count":74,"title":["Scleritis: A Paradoxical Effect of Etanercept? Etanercept-associated Inflammatory Eye Disease"],"prefix":"10.3899","volume":"39","author":[{"given":"C\u00c9CILE","family":"GAUJOUX-VIALA","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"CECILIA","family":"GIAMPIETRO","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"THOMAS","family":"GAUJOUX","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"HANG-KORNG","family":"EA","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"CL\u00c9MENT","family":"PRATI","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"PHILIPPE","family":"ORCEL","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"DANIEL","family":"WENDLING","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"FR\u00c9D\u00c9RIC","family":"LIOT\u00c9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2262","published-online":{"date-parts":[[2011,12,15]]},"reference":[{"issue":"511","key":"2018112909272990000_39.2.233.1","first-page":"e1","article-title":"[Can tumor necrosis factor inhibitors induce sclero-uveitis?]","volume":"32","author":"Le Garrec","year":"2009","journal-title":"French. J Fr Ophtalmol"},{"key":"2018112909272990000_39.2.233.2","doi-asserted-by":"publisher","DOI":"10.1053\/sarh.2001.16639"},{"key":"2018112909272990000_39.2.233.3","doi-asserted-by":"publisher","DOI":"10.1038\/ncprheum0454"},{"key":"2018112909272990000_39.2.233.4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpeds.2006.08.044"},{"key":"2018112909272990000_39.2.233.5","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2006.058248"},{"key":"2018112909272990000_39.2.233.6","doi-asserted-by":"publisher","DOI":"10.1002\/art.21197"},{"key":"2018112909272990000_39.2.233.7","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2006.052092"},{"key":"2018112909272990000_39.2.233.8","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/ken091"},{"key":"2018112909272990000_39.2.233.9","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2006.04.038"},{"key":"2018112909272990000_39.2.233.10","doi-asserted-by":"publisher","DOI":"10.1002\/art.22918"},{"key":"2018112909272990000_39.2.233.11","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(200106)45:3<252::AID-ART257>3.0.CO;2-5"},{"key":"2018112909272990000_39.2.233.12","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-009-1368-8"},{"key":"2018112909272990000_39.2.233.13","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(200002)43:2<243::AID-ANR2>3.0.CO;2-K"},{"key":"2018112909272990000_39.2.233.14","doi-asserted-by":"publisher","DOI":"10.1080\/09273940600659393"},{"key":"2018112909272990000_39.2.233.15","doi-asserted-by":"publisher","DOI":"10.1136\/bjo.87.7.925"},{"key":"2018112909272990000_39.2.233.16","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2007.077370"},{"key":"2018112909272990000_39.2.233.17","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.06-1444"},{"key":"2018112909272990000_39.2.233.18","doi-asserted-by":"publisher","DOI":"10.1136\/ard.58.2008.i32"},{"key":"2018112909272990000_39.2.233.19","first-page":"658","article-title":"Mice deficient in tumor necrosis factor receptors p55 and p75, interleukin-4, or inducible nitric oxide synthase are susceptible to endotoxin-induced uveitis","volume":"39","author":"Smith","year":"1998","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"2018112909272990000_39.2.233.20","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keh658"},{"key":"2018112909272990000_39.2.233.21","doi-asserted-by":"publisher","DOI":"10.1136\/ard.62.1.88"},{"key":"2018112909272990000_39.2.233.22","doi-asserted-by":"publisher","DOI":"10.1002\/art.10885"},{"key":"2018112909272990000_39.2.233.23","first-page":"2727","article-title":"Ocular inflammatory disease in patients with RA taking etanercept: Is discontinuation of etanercept necessary?","volume":"30","author":"Tiliakos","year":"2003","journal-title":"J Rheumatol"},{"key":"2018112909272990000_39.2.233.24","doi-asserted-by":"publisher","DOI":"10.1038\/ncprheum0225"},{"key":"2018112909272990000_39.2.233.25","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kem052"},{"key":"2018112909272990000_39.2.233.26","first-page":"136","article-title":"Orbital myositis in a rheumatoid arthritis patient during etanercept treatment","volume":"21","author":"Caramaschi","year":"2003","journal-title":"Clin Exp Rheumatol"},{"key":"2018112909272990000_39.2.233.27","doi-asserted-by":"publisher","DOI":"10.1002\/art.23440"},{"key":"2018112909272990000_39.2.233.28","first-page":"838","article-title":"Etanercept therapy-associated acute uveitis: A case report and literature review","volume":"27","author":"Wang","year":"2009","journal-title":"Clin Exp Rheumatol"},{"key":"2018112909272990000_39.2.233.29","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kep083"},{"key":"2018112909272990000_39.2.233.30","first-page":"238","article-title":"Sustained efficacy and safety, including patient-reported outcomes, with etanercept treatment over 5 years in patients with ankylosing spondylitis","volume":"28","author":"Mart\u00c3\u00adn-Mola","year":"2010","journal-title":"Clin Exp Rheumatol"}],"container-title":["The Journal of Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.3899\/jrheum.110865","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,11,29]],"date-time":"2018-11-29T13:13:06Z","timestamp":1543497186000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jrheum.org\/lookup\/doi\/10.3899\/jrheum.110865"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,12,15]]},"references-count":30,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2012,2,1]]},"published-print":{"date-parts":[[2012,2]]}},"alternative-id":["10.3899\/jrheum.110865"],"URL":"https:\/\/doi.org\/10.3899\/jrheum.110865","relation":{},"ISSN":["0315-162X","1499-2752"],"issn-type":[{"value":"0315-162X","type":"print"},{"value":"1499-2752","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,12,15]]}}}